Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) – the leading trade association representing manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices –sent a letter to the House Energy and Commerce Committee Health Subcommittee expressing support for the Protecting Access to Lifesaving Screenings Act of 2021 (H.R. 4612).
“Early detection of breast cancer via routine screening is key to beginning lifesaving treatment sooner. We urge Congress to reauthorize the PALS Act to protect ongoing access for the 22 million women at risk of losing coverage to these essential screening services,” MITA Executive Director Patrick Hope wrote in a letter addressed to Subcommittee Chairwoman Anna Eshoo (D-CA) and Committee Ranking Member Brent Guthrie (R-KY).
The PALS Act, which MITA has supported since it was originally passed in 2015, would protect annual breast cancer screening for women ages 40-49. Further, the provisions called for in the PALS Act align directly with breast cancer screening guidelines issued by clinical professional societies based on evidence-based best practices and designed to support patient-physician shared decision making.
MITA further stressed that efforts to encourage breast cancer screening are especially important as the nation seeks greater health equity, particularly among Black women who are at higher risk for breast cancer. Data suggest that improving access to screening for all women could play an important role in reducing racial disparities in breast cancer rates in women of color.
For example, according to research published in the Annals of Internal Medicine, one measure showed earlier screenings could reduce breast cancer deaths enough to shrink the gap in fatal outcomes between Black women as compared with white women by 57 percent.
To read the MITA letter to E&C leadership, click here.
MITA is the collective voice of manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging innovations. These products include: magnetic resonance imaging (MRI), medical X-Ray equipment, computed tomography (CT) scanners, ultrasound, nuclear imaging, radiopharmaceuticals, and imaging information systems. MITA Member company technologies are an important part of our nation’s healthcare infrastructure and are essential for the screening, diagnosis, staging, managing and effectively treating patients with cancer, heart disease, neurological degeneration, and numerous other medical conditions.